Is there a clinical role for oxidative stress biomarkers in atherosclerotic diseases? (original) (raw)

References

1. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F (2012) European Association for Cardiovascular P, Rehabilitation, Guidelines ESCCfP (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version, The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33(13):1635–1701. doi:10.1093/eurheartj/ehs092
   Article CAS PubMed Google Scholar
2. Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340(2):115–126
   Article CAS PubMed Google Scholar
3. Stocker R, Keaney JF Jr (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev 84(4):1381–1478
   Article CAS PubMed Google Scholar
4. Morrow JD (2005) Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 25(2):279–286. doi:10.1161/01.ATV.0000152605.64964.c0
   Article CAS PubMed Google Scholar
5. Singh R, Barden A, Mori T, Beilin L (2001) Advanced glycation end-products: a review. Diabetologia 44(2):129–146. doi:10.1007/s001250051591
   Article CAS PubMed Google Scholar
6. Li H, Horke S, Förstermann U (2013) Oxidative stress in vascular disease and its pharmacological prevention. Trends Pharmacol Sci 34(6):313–319. doi:10.1016/j.tips.2013.03.007
   Article PubMed Google Scholar
7. Schaub N, Reichlin T, Meune C, Twerenbold R, Haaf P, Hochholzer W, Niederhauser N, Bosshard P, Stelzig C, Freese M, Reiter M, Gea J, Buser A, Mebazaa A, Osswald S, Mueller C (2012) Markers of plaque instability in the early diagnosis and risk stratification of acute myocardial infarction. Clin Chem 58(1):246–256
   Article CAS PubMed Google Scholar
8. Violi F, Basili S, Nigro C, Pignatelli P (2009) Role of NADPH oxidase in atherosclerosis. Future Cardiol 5(1):83–92
   Article CAS PubMed Google Scholar
9. Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87(10):840–844
   Article CAS PubMed Google Scholar
10. Campia U, Tesauro M, Cardillo C (2012) Human obesity and endothelium-dependent responsiveness. Br J Pharmacol 165(3):561–573. doi:10.1111/j.1476-5381.2011.01661.x
    Article CAS PubMed Google Scholar
11. Babior BM, Lambeth JD, Nauseef W (2002) The neutrophil NADPH oxidase. Arch Biochem Biophys 397(2):342–344. doi:10.1006/abbi.2001.2642
    Article CAS PubMed Google Scholar
12. Loffredo L (2011) Chronic granulomatous disease. Intern Emerg Med 6(Suppl 1):125–128. doi:10.1007/s11739-011-0676-6
    Article PubMed Google Scholar
13. Pignatelli P, Carnevale R, Cangemi R, Loffredo L, Sanguigni V, Stefanutti C, Basili S, Violi F (2010) Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 30(2):360–367. doi:10.1161/ATVBAHA.109.198622
    Article CAS PubMed Google Scholar
14. Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87(1):245–313. doi:10.1152/physrev.00044.2005
    Article CAS PubMed Google Scholar
15. Khatri JJ, Johnson C, Magid R, Lessner SM, Laude KM, Dikalov SI, Harrison DG, Sung HJ, Rong Y, Galis ZS (2004) Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation 109(4):520–525. doi:10.1161/01.CIR.0000109698.70638.2B
    Article CAS PubMed Google Scholar
16. Loffredo L, Martino F, Carnevale R, Pignatelli P, Catasca E, Perri L, Calabrese CM, Palumbo MM, Baratta F, Del Ben M, Angelico F, Violi F (2012) Obesity and hypercholesterolemia are associated with NOX2 generated oxidative stress and arterial dysfunction. J Pediatr 161(6):1004–1009. doi:10.1016/j.jpeds.2012.05.042
    Article CAS PubMed Google Scholar
17. Del Ben M, Fabiani M, Loffredo L, Polimeni L, Carnevale R, Baratta F, Brunori M, Albanese F, Augelletti T, Violi F, Angelico F (2012) Oxidative stress mediated arterial dysfunction in patients with obstructive sleep apnoea and the effect of continuous positive airway pressure treatment. BMC Pulm Med 12:36. doi:10.1186/1471-2466-12-36
    Article PubMed Central PubMed Google Scholar
18. Carnevale R, Loffredo L, Pignatelli P, Nocella C, Bartimoccia S, Di Santo S, Martino F, Catasca E, Perri L, Violi F (2012) Dark chocolate inhibits platelet isoprostanes via NOX2 down-regulation in smokers. J Thromb Haemost: JTH 10(1):125–132. doi:10.1111/j.1538-7836.2011.04558.x
    Article CAS PubMed Google Scholar
19. Loffredo L, Carnevale R, Cangemi R, Angelico F, Augelletti T, Di Santo S, Calabrese CM, Della Volpe L, Pignatelli P, Perri L, Basili S, Violi F (2012) NOX2 up-regulation is associated with artery dysfunction in patients with peripheral artery disease. Int J Cardiol. doi:10.1016/j.ijcard.2012.01.069
    Google Scholar
20. Violi F, Sanguigni V, Loffredo L, Carnevale R, Buchetti B, Finocchi A, Tesauro M, Rossi P, Pignatelli P (2006) Nox2 is determinant for ischemia-induced oxidative stress and arterial vasodilatation: a pilot study in patients with hereditary Nox2 deficiency. Arterioscler Thromb Vasc Biol 26(8):e131–e132. doi:10.1161/01.ATV.0000229710.13054.2d
    Article CAS PubMed Google Scholar
21. Loffredo L, Carnevale R, Sanguigni V, Plebani A, Rossi P, Pignata C, De Mattia D, Finocchi A, Martire B, Pietrogrande MC, Martino S, Gambineri E, Giardino G, Soresina AR, Martino F, Pignatelli P, Violi F (2013) Does NADPH oxidase deficiency cause artery dilatation in humans? Antioxid redox signal 18(12):1491–1496
    Article CAS PubMed Google Scholar
22. Angelico F, Loffredo L, Pignatelli P, Augelletti T, Carnevale R, Pacella A, Albanese F, Mancini I, Di Santo S, Del Ben M, Violi F (2012) Weight loss is associated with improved endothelial dysfunction via NOX2-generated oxidative stress down-regulation in patients with the metabolic syndrome. Intern Emerg Med 7(3):219–227. doi:10.1007/s11739-011-0591-x
    Article PubMed Google Scholar
23. Basili S, Pignatelli P, Tanzilli G, Mangieri E, Carnevale R, Nocella C, Di Santo S, Pastori D, Ferroni P, Violi F (2011) Anoxia-reoxygenation enhances platelet thromboxane A2 production via reactive oxygen species-generated NOX2: effect in patients undergoing elective percutaneous coronary intervention. Arterioscler Thromb Vasc Biol 31(8):1766–1771. doi:10.1161/ATVBAHA.111.227959
    Article CAS PubMed Google Scholar
24. Violi F, Pignatelli P, Pignata C, Plebani A, Rossi P, Sanguigni V, Carnevale R, Soresina A, Finocchi A, Cirillo E, Catasca E, Angelico F, Loffredo L (2013) Reduced atherosclerotic burden in subjects with genetically determined low oxidative stress. Arterioscler Thromb Vasc Biol 33(2):406–412. doi:10.1161/ATVBAHA.112.300438
    Article CAS PubMed Google Scholar
25. Liu Y, Davidson BP, Yue Q, Belcik T, Xie A, Inaba Y, McCarty OJ, Tormoen GW, Zhao Y, Ruggeri ZM, Kaufmann BA, Lindner JR (2013) Molecular imaging of inflammation and platelet adhesion in advanced atherosclerosis effects of antioxidant therapy with NADPH oxidase inhibition. Circ Cardiovasc Imaging 6(1):74–82. doi:10.1161/CIRCIMAGING.112.975193
    Article PubMed Central PubMed Google Scholar
26. Pignatelli P, Sanguigni V, Lenti L, Ferro D, Finocchi A, Rossi P, Violi F (2004) gp91phox-dependent expression of platelet CD40 ligand. Circulation 110(10):1326–1329. doi:10.1161/01.CIR.0000134963.77201.55
    Article CAS PubMed Google Scholar
27. Cangemi R, Celestini A, Calvieri C, Carnevale R, Pastori D, Nocella C, Vicario T, Pignatelli P, Violi F (2012) Different behaviour of NOX2 activation in patients with paroxysmal/persistent or permanent atrial fibrillation. Heart 98(14):1063–1066. doi:10.1136/heartjnl-2012-301952
    Article CAS PubMed Google Scholar
28. Cangemi R, Celestini A, Del Ben M, Pignatelli P, Carnevale R, Proietti M, Calabrese CM, Basili S, Violi F (2012) Role of platelets in NOX2 activation mediated by TNFalpha in heart failure. Intern Emerg Med. doi:10.1007/s11739-012-0837-2
    PubMed Google Scholar
29. Cangemi R, Pignatelli P, Carnevale R, Nigro C, Proietti M, Angelico F, Lauro D, Basili S, Violi F (2012) Platelet isoprostane overproduction in diabetic patients treated with aspirin. Diabetes 61(6):1626–1632. doi:10.2337/db11-1243
    Article CAS PubMed Google Scholar
30. Pignatelli P, Carnevale R, Di Santo S, Bartimoccia S, Sanguigni V, Lenti L, Finocchi A, Mendolicchio L, Soresina AR, Plebani A, Violi F (2011) Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler Thromb Vasc Biol 31(2):423–434. doi:10.1161/ATVBAHA.110.217885
    Article CAS PubMed Google Scholar
31. Morrow JD, Roberts LJ 2nd (1999) Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods Enzymol 300:3–12
    Article CAS PubMed Google Scholar
32. Violi F, Sanguigni V, Carnevale R, Plebani A, Rossi P, Finocchi A, Pignata C, De Mattia D, Martire B, Pietrogrande MC, Martino S, Gambineri E, Soresina AR, Pignatelli P, Martino F, Basili S, Loffredo L (2009) Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation 120(16):1616–1622
    Article CAS PubMed Google Scholar
33. Hummel SL, Seymour EM, Brook RD, Kolias TJ, Sheth SS, Rosenblum HR, Wells JM, Weder AB (2012) Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction. Hypertension 60(5):1200–1206. doi:10.1161/HYPERTENSIONAHA.112.202705
    Article CAS PubMed Central PubMed Google Scholar
34. Davi G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, Basili S, Ciabattoni G, Patrono C (2003) Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 107(25):3199–3203. doi:10.1161/01.CIR.0000074205.17807.D0
    Article CAS PubMed Google Scholar
35. Davies SS, Roberts LJ 2nd (2011) F2-isoprostanes as an indicator and risk factor for coronary heart disease. Free Radic Biol Med 50(5):559–566. doi:10.1016/j.freeradbiomed.2010.11.023
    Article CAS PubMed Central PubMed Google Scholar
36. Puccetti L, Santilli F, Pasqui AL, Lattanzio S, Liani R, Ciani F, Ferrante E, Ciabattoni G, Scarpini F, Ghezzi A, Auteri A, Davi G (2011) Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 214(1):122–128. doi:10.1016/j.atherosclerosis.2010.10.006
    Article CAS PubMed Google Scholar
37. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C (2002) Platelet activation in obese women: role of inflammation and oxidant stress. JAMA: J Am Med Assoc 288(16):2008–2014
    Article CAS Google Scholar
38. Shishehbor MH, Zhang R, Medina H, Brennan ML, Brennan DM, Ellis SG, Topol EJ, Hazen SL (2006) Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med 41(11):1678–1683. doi:10.1016/j.freeradbiomed.2006.09.001
    Article CAS PubMed Central PubMed Google Scholar
39. Woodward M, Croft KD, Mori TA, Headlam H, Wang XS, Suarna C, Raftery MJ, MacMahon SW, Stocker R (2009) Association between both lipid and protein oxidation and the risk of fatal or non-fatal coronary heart disease in a human population. Clin Sci 116(1):53–60. doi:10.1042/CS20070404
    Article CAS PubMed Google Scholar
40. Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Di Gregorio D, Bucciarelli T, Davi G, Cuccurullo F, Patrono C (2000) Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102(9):1007–1013
    Article CAS PubMed Google Scholar
41. Ward NC, Croft KD, Blacker D, Hankey GJ, Barden A, Mori TA, Puddey IB, Beer CD (2011) Cytochrome P450 metabolites of arachidonic acid are elevated in stroke patients compared with healthy controls. Clin Sci 121(11):501–507. doi:10.1042/CS20110215
    Article CAS PubMed Google Scholar
42. Iuliano L, Pratico D, Greco C, Mangieri E, Scibilia G, FitzGerald GA, Violi F (2001) Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol 37(1):76–80
    Article CAS PubMed Google Scholar
43. LeLeiko RM, Vaccari CS, Sola S, Merchant N, Nagamia SH, Thoenes M, Khan BV (2009) Usefulness of elevations in serum choline and free F2)-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome. Am J Cardiol 104(5):638–643. doi:10.1016/j.amjcard.2009.04.047
    Article CAS PubMed Google Scholar
44. Carr AC, McCall MR, Frei B (2000) Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 20(7):1716–1723
    Article CAS PubMed Google Scholar
45. Hazen SL, Heinecke JW (1997) 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Investig 99(9):2075–2081. doi:10.1172/JCI119379
    Article CAS PubMed Google Scholar
46. Marsche G, Furtmuller PG, Obinger C, Sattler W, Malle E (2008) Hypochlorite-modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro. Cardiovasc Res 79(1):187–194. doi:10.1093/cvr/cvn051
    Article CAS PubMed Google Scholar
47. Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JF Jr, Hazen SL (2004) Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 110(9):1134–1139. doi:10.1161/01.CIR.0000140262.20831.8F
    Article CAS PubMed Central PubMed Google Scholar
48. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P (2001) Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 158(3):879–891. doi:10.1016/S0002-9440(10)64036-9
    Article CAS PubMed Google Scholar
49. Exner M, Minar E, Mlekusch W, Sabeti S, Amighi J, Lalouschek W, Maurer G, Bieglmayer C, Kieweg H, Wagner O, Schillinger M (2006) Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol. J Am Coll Cardiol 47(11):2212–2218. doi:10.1016/j.jacc.2006.01.067
    Article CAS PubMed Google Scholar
50. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL (2001) Association between myeloperoxidase levels and risk of coronary artery disease. JAMA: J Am Med Assoc 286(17):2136–2142
    Article CAS Google Scholar
51. Kubala L, Lu G, Baldus S, Berglund L, Eiserich JP (2008) Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. Clin Chim Acta: Int J Clin Chem 394(1–2):59–62. doi:10.1016/j.cca.2008.04.001
    Article CAS Google Scholar
52. Tretjakovs P, Jurka A, Bormane I, Mikelsone I, Elksne K, Krievina G, Reihmane D, Verbovenko J, Bahs G (2012) Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina. Clinica Chim Acta: Int J of Clin Chem 413(1–2):25–29. doi:10.1016/j.cca.2011.10.009
    Article CAS Google Scholar
53. Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM (2007) Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 50(2):159–165. doi:10.1016/j.jacc.2007.03.033
    Article CAS PubMed Google Scholar
54. Brevetti G, Schiano V, Laurenzano E, Giugliano G, Petretta M, Scopacasa F, Chiariello M (2008) Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease. Eur Heart J 29(2):224–230. doi:10.1093/eurheartj/ehm587
    Article CAS PubMed Google Scholar
55. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL (2003) Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349(17):1595–1604. doi:10.1056/NEJMoa035003
    Article CAS PubMed Google Scholar
56. Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, Rifai N, Cannon CP, Hazen SL (2008) Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 29(9):1096–1102. doi:10.1093/eurheartj/ehn071
    Article CAS PubMed Central PubMed Google Scholar
57. Iuliano L, Mauriello A, Sbarigia E, Spagnoli LG, Violi F (2000) Radiolabeled native low-density lipoprotein injected into patients with carotid stenosis accumulates in macrophages of atherosclerotic plaque: effect of vitamin E supplementation. Circulation 101(11):1249–1254
    Article CAS PubMed Google Scholar
58. Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL (1990) Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10(3):325–335
    Article CAS PubMed Google Scholar
59. Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, McConnell JP, Kornman KS, Berger PB (2007) Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 48(2):425–433. doi:10.1194/jlr.M600361-JLR200
    Article CAS PubMed Google Scholar
60. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D (1998) Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98(15):1487–1494
    Article CAS PubMed Google Scholar
61. Sigala F, Kotsinas A, Savari P, Filis K, Markantonis S, Iliodromitis EK, Gorgoulis VG, Andreadou I (2010) Oxidized LDL in human carotid plaques is related to symptomatic carotid disease and lesion instability. J Vasc Surg 52(3):704–713. doi:10.1016/j.jvs.2010.03.047
    Article PubMed Google Scholar
62. Naruko T, Ueda M, Ehara S, Itoh A, Haze K, Shirai N, Ikura Y, Ohsawa M, Itabe H, Kobayashi Y, Yamagishi H, Yoshiyama M, Yoshikawa J, Becker AE (2006) Persistent high levels of plasma oxidized low-density lipoprotein after acute myocardial infarction predict stent restenosis. Arterioscler Thromb Vasc Biol 26(4):877–883. doi:10.1161/01.ATV.0000209886.31510.7f
    Article CAS PubMed Google Scholar
63. Shimada K, Mokuno H, Matsunaga E, Miyazaki T, Sumiyoshi K, Miyauchi K, Daida H (2004) Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis 174(2):343–347. doi:10.1016/j.atherosclerosis.2004.01.029
    Article CAS PubMed Google Scholar
64. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, Goodpaster B, Harris TB (2004) The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 53(4):1068–1073
    Article CAS PubMed Google Scholar
65. Wu T, Willett WC, Rifai N, Shai I, Manson JE, Rimm EB (2006) Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women? J Am Coll Cardiol 48(5):973–979. doi:10.1016/j.jacc.2006.03.057
    Article CAS PubMed Google Scholar
66. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB (2005) Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353(1):46–57. doi:10.1056/NEJMoa043175
    Article CAS PubMed Google Scholar
67. Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, Xu Q, Bergmark C, Weger S, Oberhollenzer F, Witztum JL (2006) Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol 47(11):2219–2228. doi:10.1016/j.jacc.2006.03.001
    Article CAS PubMed Google Scholar
68. Ravandi A, Boekholdt SM, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, Miller ER, Benessiano J, Tedgui A, Witztum JL, Khaw KT, Tsimikas S (2011) Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res 52(10):1829–1836. doi:10.1194/jlr.M015776
    Article CAS PubMed Google Scholar
69. Koenig W, Karakas M, Zierer A, Herder C, Baumert J, Meisinger C, Thorand B (2011) Oxidized LDL and the risk of coronary heart disease: results from the MONICA/KORA Augsburg Study. Clin Chem 57(8):1196–1200. doi:10.1373/clinchem.2011.165134
    Article CAS PubMed Google Scholar
70. Thornalley PJ (1998) Cell activation by glycated proteins: AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol 44(7):1013–1023
    CAS PubMed Google Scholar
71. Ceriello A (1999) Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr Metab 12(1):42–46
    CAS PubMed Google Scholar
72. Kiuchi K, Nejima J, Takano T, Ohta M, Hashimoto H (2001) Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 85(1):87–91
    Article CAS PubMed Google Scholar
73. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, Lyons TJ (1993) Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Investig 91(6):2470–2478. doi:10.1172/JCI116482
    Article CAS PubMed Google Scholar
74. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A (2003) The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108(9):1070–1077. doi:10.1161/01.CIR.0000086014.80477.0D
    Article CAS PubMed Google Scholar
75. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y, Ohtoshi K, Hayaishi-Okano R, Kosugi K, Hori M, Yamasaki Y (2005) Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 28(11):2716–2721
    Article CAS PubMed Google Scholar
76. Lapolla A, Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Baccarin L, Laverda B, Fedele D (2007) Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 30(3):670–676. doi:10.2337/dc06-1508
    Article CAS PubMed Google Scholar
77. Onorato JM, Thorpe SR, Baynes JW (1998) Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann N Y Acad Sci 854:277–290
    Article CAS PubMed Google Scholar
78. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, Bei R, Ucchino S, Spigonardo F, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A, Cipollone F (2006) Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 26(12):2716–2723. doi:10.1161/01.ATV.0000249630.02085.12
    Article CAS PubMed Google Scholar
79. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, Gaziano JM (2008) Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA: J Am Med Assoc 300(18):2123–2133. doi:10.1001/jama.2008.600
    Article CAS Google Scholar
80. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ (2003) Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 361(9374):2017–2023. doi:10.1016/S0140-6736(03)13637-9
    Article CAS PubMed Google Scholar

Download references